
European Association for the Study of Diabetes (EASD) Annual Meeting 2025
Vienna, Austria 15 September 2025 - 19 September 2025
JAK inhibitor a new hope for new-onset T1D?
02 Oct 2025
byAudrey Abella
The 2-year outcomes from the phase II BANDIT* trial confirm the potential of the Janus kinase (JAK) inhibitor baricitinib for the treatment of new-onset type 1 diabetes (T1D).